A detailed history of Alliancebernstein L.P. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 179,620 shares of TSHA stock, worth $777,754. This represents 0.0% of its overall portfolio holdings.

Number of Shares
179,620
Previous 108,250 65.93%
Holding current value
$777,754
Previous $150,000 176.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$1.13 - $2.9 $80,648 - $206,973
71,370 Added 65.93%
179,620 $414,000
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $25,426 - $31,119
12,650 Added 13.23%
108,250 $217,000
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $195,024 - $398,652
95,600 New
95,600 $214,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $209M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.